Three months on, Eli Lilly has closed the books on its search for a new chief financial officer. And as with its previous CFO ...

When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...

With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing ...

BMS ran its first C2C4C event in 2014, when an employee worked with colleagues to put together a team of 53 oncology staffers ...

Why is PDA’s Universe of Pre-Filled Syringes and Injection Devices Conference the must-attend event of the year? Get an ...

Gilead Sciences has been looking for a win for Trodelvy after two surprise trial failures earlier this year. But it looks ...

After opting out of Teva’s $4.25 billion national opioid settlement last year, the city of Baltimore has secured its own payout through a settlement deal worth $80 million. | The city scored its own ...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | ...

The Rybrevant-Lazcluze combo lowered the risk of death by 23% compared with Tagrisso in an updated analysis of the phase 3 ...

A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. | A year after missing on a trial ...

It’s as you were at the top of the TV drug ad spending table as AbbVie continues its 2024 domination as total spending across ...

GSK is heading into the weekend with a win for its respiratory blockbuster Nucala—but for now, the details are slim. On ...